Partner II Announcement

The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves Trial II

We are pleased to inform you that the Nebraska Heart Hospital is now participating in The PARTNER II Trial, one of the few centers in the country and first in Nebraska to provide this innovative therapy.

This trial randomizes patients diagnosed with severe, symptomatic calcific native aortic stenosis who are at increased surgical risk to either transcatheter aortic valve replacement (TAVR) with the Edwards SAPIEN XT transcatheter heart valve (THV) or traditional aortic valve replacement (AVR).

You likely see patients in your practice who suffer from severe native aortic valve stenosis and are at increased risk for surgery. Current ACC/AHA Guidelines for the Management of Patients with Valvular Heart Disease indicate surgical AVR for virtually all patients with severe, symptomatic aortic stenosis. Without replacement of the aortic valve, this disease is life-threatening as previous studies have shown that 50 percent of patients will not survive more than an average of two years after the onset of symptoms.

The SAPIEN XT aortic valve is delivered via a catheter-based approach without a median sternotomy or the use of cardiopulmonary bypass with the average recovery period for patients being one to two weeks. Our Heart Team dedicated to The PARTNER II Trial, which includes a cardiothoracic surgeon, interventional cardiologist, echocardiographer, anesthesiologist, and pre and postoperative care providers, takes a rigorous, multi-disciplinary approach to patient care in this trial to ensure appropriate patient selection and optimal outcomes.

It is our hope that, as you see patients in your daily practice at increased risk for AVR surgery, you would consider referring them to us for further evaluation per the criteria of the trial. We are confident that the local availability of transcatheter therapeutic options will enable more patients to receive treatment for their valve disease.

If you would like additional information regarding this trial, please contact our Clinical Research Department at 402-328-3977.

Addtional Resources: